All In Biotech

NDA 020387 · Organon

Hyzaar

Hydrochlorothiazide, Losartan Potassium · Oral · Thiazide Diuretic

Last checked: Nov 19, 2026Latest source record: Jun 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Apr 28, 1995

Approved uses

4

Original approval plus efficacy supplements

Registered trials

450

138 Phase 3, 14 recruiting

FAERS reports

11,595

7,498 serious, 698 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue HYZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue HYZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

What it is approved for

From the label in effect Nov 26, 2025.

HYZAAR is a combination of losartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) 1.1 Hypertension HYZAAR ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is...

Mechanism: Losartan Potassium Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor found in many tissues (e.g., vascular...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • HYZAAR · HYDROCHLOROTHIAZIDE 25MG; LOSARTAN POTASSIUM 100MG · TABLET, ORAL · Prescription · TE AB
  • HYZAAR · HYDROCHLOROTHIAZIDE 12.5MG; LOSARTAN POTASSIUM 100MG · TABLET, ORAL · Prescription · TE AB
  • HYZAAR · HYDROCHLOROTHIAZIDE 12.5MG; LOSARTAN POTASSIUM 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrochlorothiazide" as an intervention, any sponsor and status, largest first.

All 450 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea773
  • drug ineffective742
  • fatigue692
  • dizziness594
  • headache563
  • diarrhoea536
  • pain515
  • dyspnoea513
  • arthralgia453
  • asthenia451
  • vomiting407
  • hypertension380

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004470
2005589
2006625
2007621
2008610
2009677
2010843
2011766
2012760
2013445
2014616
2015652
2016722
2017493
2018506
2019568
2020381
2021233
2022275
2023190
2024179
2025229
2026144

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Hyzaar (Losartan/Hydrochlorothiazide)

2024 spending

$1.4M

Beneficiaries

883

3,947 claims

Per beneficiary

$1,626

$5.50 per unit

View as table
YearSpending
2020$0
2021$493,683
2022$1,861,338
2023$1,745,229
2024$1,435,374

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,366 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.